VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Friday, January 2, 2026

Stock Comparison

AstraZeneca PLC vs Gartner, Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

AstraZeneca PLC

AZN · London Stock Exchange

Market cap (USD)
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryGB
Data as of2026-01-02
Moat score
71/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.

View AZN analysis

Gartner, Inc.

IT · New York Stock Exchange

Market cap (USD)$18.7B
Gross margin (TTM)68.2%
Operating margin (TTM)15.6%
Net margin (TTM)13.7%
SectorTechnology
IndustryInformation Technology Services
CountryUS
Data as of2025-12-30
Moat score
74/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Gartner, Inc.'s moat claims, evidence, and risks.

View IT analysis

Comparison highlights

  • Moat score gap: Gartner, Inc. leads (74 / 100 vs 71 / 100 for AstraZeneca PLC).
  • Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); Gartner, Inc. has 3 segments (81.8% in Insights).
  • Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; Gartner, Inc. has 4 across 2.

Primary market context

AstraZeneca PLC

Oncology

Market

Innovator oncology therapeutics (branded prescription medicines)

Geography

Global

Customer

Hospitals, oncology clinics, payers

Role

Innovator biopharmaceutical company

Revenue share

41%

Gartner, Inc.

Insights

Market

IT research and executive advisory subscriptions (insights, benchmarks, and expert access)

Geography

Global

Customer

Enterprise executives and teams (technology leaders and business function leaders)

Role

Subscription-based analyst and advisory provider

Revenue share

81.8%

Side-by-side metrics

AstraZeneca PLC
Gartner, Inc.
Ticker / Exchange
AZN - London Stock Exchange
IT - New York Stock Exchange
Market cap (USD)
n/a
$18.7B
Gross margin (TTM)
n/a
68.2%
Operating margin (TTM)
n/a
15.6%
Net margin (TTM)
n/a
13.7%
Sector
Healthcare
Technology
Industry
n/a
Information Technology Services
HQ country
GB
US
Primary segment
Oncology
Insights
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Strong
Strong
Moat score
71 / 100
74 / 100
Moat domains
Legal, Supply, Demand
Demand, Network
Last update
2026-01-02
2025-12-30

Moat coverage

Shared moat types

Brand Trust

AstraZeneca PLC strengths

Regulated Standards PipeIP Choke PointCapex Knowhow Scale

Gartner, Inc. strengths

Switching Costs GeneralSuite BundlingTwo Sided Network

Segment mix

AstraZeneca PLC segments

Full profile >

Oncology

Oligopoly

41%

Cardiovascular, Renal and Metabolism (CVRM)

Competitive

23%

Respiratory & Immunology (R&I)

Oligopoly

15%

Vaccines & Immune Therapies (V&I)

Oligopoly

3%

Rare Disease

Oligopoly

16%

Other Medicines

Competitive

2%

Gartner, Inc. segments

Full profile >

Insights

Oligopoly

81.8%

Conferences

Competitive

9.3%

Consulting

Competitive

8.9%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.